Immunotherapy First for BRAF Melanoma Edges Out Targeted Combination

(MedPage Today) -- First-line immunotherapy for BRAF-positive melanoma, followed by targeted therapy at progression, led to a "clinically meaningful" survival benefit, a randomized trial showed.
Combination immunotherapy with nivolumab (Opdivo...